15 hrs ago
Humira Patent Invalid for Obviousness Type Double Patenting
In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering AbbVie's Humira product is invalid under the doctrine of obviousness-type double patenting.
Findings on Nanoparticles Detailed by Investigators at Xiamen...
In this paper, we report a novel strategy of preparing methotrexate nanopartides based on chitosan and methoxypoly used as nanocarriers to enhance their targeting and prolong blood circulation."
CHMP Issues Positive Opinion For Roche RA Drug Label Expansion
On 24 July 2014 , the Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal p roduct RoActemra .
Presence of the full-length KIR2DS4 gene reduces the chance of...
KIR genes coding for natural killer cell immunoglobulin-like receptors, KIR, influence the effector and regulatory function of NK cells as well as some subpopulations of T lymphocytes depending on presence of ligands .
CHMP issues positive opinion for Roche RA drug label expansion
The EMA's Committee for Medicinal Products for Human Use issues a positive opinion supporting the approval of Roche's RoActemra/ Actemra as as treatment for patients with early rheumatoid arthritis not previously treated with methotrexate .